A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:
Back to home » Top Stories » IAS 2009
IAC 2008 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
Cape Town, South Africa
July 19-22, 2009

More Than Half Could Need Treatment Within 2 Years of Infection

July 21, 2009

By David Evans

If HIV treatment guidelines were updated to recommend beginning treatment at 500 CD4 cells, then more than half of all people with HIV would need to initiate antiretroviral (ARV) treatment within two years of becoming infected. This startling finding was presented Monday, July 20, at the Fifth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town.

Due to a number of recent studies showing detrimental effects of uncontrolled HIV replication—even at fairly high CD4 cell counts—international HIV treatment guidelines may begin recommending that people start ARV therapy when their CD4 counts drop below 500. The current recommendation is to start treatment at 350. Researchers have long known that a substantial number of people with HIV have significant CD4 cell drops shortly after infection, but no studies have examined how many people would need to start HIV treatment soon after infection, and how quickly this would occur.

Sara Lodi, PhD, from the Medical Research Council Clinical Trials Unit in London, and her colleagues with the CASCADE cohort study looked at the time it took for 11,702 recently infected individuals to have their CD4 counts drop below 500. People have been followed in CASCADE since 1992. Lodi’s team looked at CD4 counts at 6, 12, 24 and 36 months after people first had a positive HIV antibody test. The proportions of people whose CD4 counts dropped below 500 were 8 percent at 6 months, 28 percent at 1 year, 57 percent at 2 years, and 70 percent at 3 years after seroconverstion.

Lodi and her colleagues also found that people’s CD4 cells dropped more quickly the older they were when they became infected. In addition, people infected before 1997 appeared to progress more slowly than people infected after 1997.

The authors state that this data can help policymakers and researchers determine what kind of health care resources will be needed if treatment guidelines change. This will be especially vital if universal HIV testing becomes more widespread, as a third or more of people who test positive in the United States and Western Europe currently wait to get tested until their CD4 counts have dropped below 200.

Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       

Funding for coverage of this conference is provided, in part, by an unrestricted educational grant from Tibotec Therapeutics, a division of Ortho Biotech Products, LP.
More from IAS 2009

Starting and Switching Treatment

July 31, 2009
South African Study: Nurses Comparable to Doctors in Monitoring HIV Management
July 30, 2009
Acyclovir Slows HIV Disease Progression, But Fails to Reduce HIV Transmission
July 27, 2009
Switch From Norvir-Boosted to Unboosted Reyataz Safe and Effective
July 24, 2009
Kaletra Is Better Than Viramune for Kids Exposed to Viramune at Birth
Study Hints That Micronutrient Supplement Might Help HIV-Positive Kids
A Quad NRTI Regimen Fails to Perform
July 23, 2009
HIV Treatment Effective Without Laboratory Monitoring in Southern Africa Study
Viramune Has Similar Efficacy to Reyataz
July 22, 2009
Pediatric Viramune May Still Work as Treatment in Kids Exposed at Birth
Triple-Drug Regimen Works Well for Heavily Treatment-Experienced Patients
Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment
People on Sustiva Have Less Risk for Treatment Failure Than People on Kaletra
Substantial Single-Year Gains in ARV Access in 2008
July 21, 2009
Isentress Going Strong After Three Years in Treatment Starters
More Than Half Could Need Treatment Within 2 Years of Infection
July 20, 2009
Pediatric HIV: Successes and Challenges
GRACE Shows Similar Treatment Response Rates in Women and Men on Prezista Treatment
CD4 Counts Key to AIDS-Free Survival While on HIV Treatment

Women and HIV

July 28, 2009
Menopause May Occur Earlier in HIV-Positive Women
July 24, 2009
No Transmission and Few Birth Defects in Babies Born to African Mothers on HIV Treatment
July 22, 2009
Mma Bana: Lowest-Ever Mother-to-Child HIV Transmission Rates With Combo Therapy in Botswana
July 20, 2009
GRACE Shows Similar Treatment Response Rates in Women and Men on Prezista Treatment

HIV/AIDS Complications

August 3, 2009
New Studies Question Abacavir Role in Heart Attack Risk
July 30, 2009
Perhaps More Lipodystrophy With Sustiva?
July 29, 2009
High Prevalence of Vitamin D Deficiency in HIV-Positive Men
July 28, 2009
Menopause May Occur Earlier in HIV-Positive Women
July 27, 2009
Chronic Stress and Non-AIDS Diseases—Is There a Link?
July 23, 2009
Zinc Supplements Prevent Immune Decline in Chronic Substance Users
Efavirenz, Race Linked to Vitamin D Deficiency
Cancer Rates Are Lower, but Still Present at Higher CD4 Levels
More Than Half of People With HIV Might Have Cognitive Impairment
July 22, 2009
ARV Therapy of Little Benefit in Preventing Anal Cancer
ARV Treatment Eases Cape Town TB Rates
July 21, 2009
ARV Treatment Protects Against Malaria in Ugandan Study

Experimental HIV Drugs

July 28, 2009
Once- vs. Twice-Daily Kaletra for Treatment Veterans
July 27, 2009
Two Studies Explore Switch to Boosted Prezista Monotherapy
July 22, 2009
Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment
July 21, 2009
Selzentry Comparable to Sustiva After 96 Weeks in Treatment Naives
Shionogi-GSK Integrase Inhibitor Shows Promise

HIV Transmission and Prevention

July 30, 2009
Acyclovir Slows HIV Disease Progression, But Fails to Reduce HIV Transmission
July 24, 2009
No Transmission and Few Birth Defects in Babies Born to African Mothers on HIV Treatment
July 22, 2009
Mma Bana: Lowest-Ever Mother-to-Child HIV Transmission Rates With Combo Therapy in Botswana
July 21, 2009
Circumcision Protects Insertive MSM Partners

Global HIV/AIDS

July 21, 2009
ARV Treatment Protects Against Malaria in Ugandan Study


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.